UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Sep

    29

    New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

    Read More Share:linkedin| twitter| email| facebook

    Aug

    07

    New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    Apr

    23

    "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    Apr

    23

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

    Read More Share:linkedin| twitter| email| facebook

    Apr

    23

    UCB Showcases Approach to Creating Patient Value in Immuno-Dermatology

    At UCB, we have come to develop a deep understanding of the patient experience and the unmet needs of people living with immuno-dermatological conditions. As we join for the American Academy of Dermatology VMX 2021 Conference, read from Rhonda Peebles, our Head of U.S. Dermatology, on UCB’s approach to creating value for patients.

    Read More Share:linkedin| twitter| email| facebook

    Feb

    05

    The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)